Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib in PTEN-Mutated Advanced Cancers (MATCH Subprotocol Z1H)
NCT06400238Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2018
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copanlisib in lymphoma, solid tumor and multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 3 years. Started Oct 2018; status: active, not recruiting.
02
Drugs
copanlisib
03
Conditions
lymphomasolid tumormultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06400238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06400238.